UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2021

 

Commission File Number: 001-39137

 

AnPac Bio-Medical Science Co., Ltd.

(Registrant’s name)

 

801 Bixing Street, Bihu County

Lishui, Zhejiang Province 323006

The People’s Republic of China

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ¨

 

 

 

 

 

 

Explanatory Note:

 

The document attached as exhibit 5.1 to this Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 initially filed with the U.S. Securities and Exchange Commission on May 28, 2021 (Registration No. 333-256630) and shall be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

On November 15, 2021, AnPac Bio-Medical Science Co., Ltd. (the "Company") closed its previously announced underwritten public offering of 1,132,111 of its American Depositary Shares ("shares") at a public offering price of $2.22 per share. Gross proceeds before deducting the underwriting discount and other offering expenses payable by the Company are approximately $2.5 million.

 

Exhibit Index:

 

5.1 Opinion of Maples and Calder (Hong Kong) LLP regarding the validity of the securities being registered

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      AnPac Bio-Medical Science Co., Ltd.
      (Registrant)
       
Date: November 15, 2021   By: /s/ Chris Chang Yu
    Name: Dr. Chris Chang Yu
    Title: Chairman of the Board of Directors and Chief Executive Officer

 

 

AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AnPac Bio Medical Science Charts.
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AnPac Bio Medical Science Charts.